1. South Korea Stocks

  2. •

    Health technology

  3. •

    Pharmaceuticals: major
UNION KOREA PHARM CO.,Ltd

UNION KOREA PHARM CO.,Ltd

KKRX:080720
8,175.00
KRW
0.00
(0.00%)
-4,761.79EPS
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
29,159.11
31,318.34
33,557.57
30,701.19
24,191.33
23,202.08
18,654.67
24,861.28
26,242.59
21,287.62
15,096.97
4,987.45
Basic EPS, GAAP
-3,775.12
2,915.88
2,040.01
3,273.44
194.02
-4,293.43
-4,290.43
-378.04
-7,542.75
-8,682.87
-12,790.28
-4,761.79
Free Cash Flow per Basic Share
-4,022.69
-309.27
2,544.68
-5,427.07
-9,109.31
-4,761.78
-2,067.66
-3,454.97
-485.16
-221.9
-520.76
-321.9
Dividend per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Book Value per Share
7,522.13
9,851.89
11,315.46
27,142.09
27,253.24
25,953.29
20,778.37
20,199.93
12,590.27
3,405.25
-9,504.3
1,268.57
Tangible Book Value per Share
7,075.25
9,463.76
10,848.97
26,539.39
26,699.59
25,189.34
20,083.32
19,560.38
12,141.66
3,097.25
-9,757.37
1,247.43
Basic Weighted Avg Shares
2
2
2
2
2
2
3
2
2
2
2
5
Sales/Revenue/Turnover
44,190
47,470
50,846
54,662
51,264
50,379
48,304
61,293
63,169
51,280
36,378
25,454
Operating Margin (%)
0.92
13.34
15.51
14.21
1.54
-21.5
-21.97
2.07
-8.28
-26.32
-47.37
-60.41
Depreciation Expense
1,552
1,664
1,944
1,891
2,474
3,747
4,226
3,994
3,890
2,877
1,803
1,486
Net Income, GAAP
-5,721
4,420
3,091
5,828
411
-9,322
-11,109
-932
-18,156
-20,916
-30,820
-24,302
Effective Tax Rate (%)
- -
18.33
57.01
14.96
29.87
- -
- -
198.78
- -
- -
- -
- -
Profit Margin (%)
-12.95
9.31
6.08
10.66
0.8
-18.5
-23
-1.52
-28.74
-40.79
-84.72
-95.48
Working Capital
6,712
12,002
8,202
39,830
23,996
21,019
14,305
-4,422
-9,327
-23,801
-42,373
11,093
LT Debt
3,191
4,993
2,288
5,557
8,373
4,140
21,087
3,032
3,080
231
96
74
Total Equity
15,469
20,260
23,270
57,812
58,048
68,369
52,341
48,612
30,324
8,205
-22,901
33,677
Return on Invested Capital (%)
- -
13.63
8.15
12.65
0.85
- -
- -
-1.72
- -
- -
- -
- -
Return on Capital (%)
- -
12.71
8.01
11.12
1.09
- -
- -
-4.3
- -
- -
- -
- -
Return on Common Equity (%)
- -
24.74
14.2
14.38
0.71
-14.75
-18.41
-1.85
-46
-108.57
- -
-137.86

Capital Structure

KRW

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
ST Debt
21,337
23,318
5,136
LT Borrowings
- -
- -
- -
LT Finance Leases
96
55
74
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
2
2
27
Market Capitalization
- -
- -
- -

Working Capital

KRW

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
Total Current Assets
21,550
22,352
53,069
Cash, Cash Equivalents & STI
6,581
7,097
37,432
Accounts Receivable, Net
7,462
6,216
5,813
Inventories
5,387
5,736
7,538
Total Current Liabilities
63,924
66,646
41,976
Payables & Accruals
- -
- -
- -
ST Debt
21,337
23,318
5,136
Deferred Revenue
- -
- -
- -

Growth Rates

KRW

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
-30.78%
-104.05%
-379.11%
Free Cash Flow
-130.7%
1.02%
134.75%
Net Income, GAAP
-74.09%
367.63%
47.35%
Sales/Revenue/Turnover
-0.8%
-4.41%
-29.06%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

KRW

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
16,533
15,043
15,771
3,933
51,280
2025
12,617
10,152
7,129
6,481
36,378
2026
5,900
5,944
- -
- -
- -

Quarterly Earnings Per Share

KRW

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
-1,245.12
-1,587.16
-615.06
-5,283.15
-8,682.87
2025
-1,062.11
-1,704.17
-4,572.9
-5,450.33
-12,790.28
2026
-948.44
162.02
- -
- -
- -

Quarterly Dividends Per Share

KRW

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -

Company Description

Company Profile APIChatGPT
CEO
Kwang-Hyun Sung
Full Time Employees
123
Sector
Health technology
Industry
Pharmaceuticals: major
Address
Wonju-si South Korea
IPO Date
Jul 26, 2018
Website
ukp.co.kr
Similar Companies
Eli Lilly and Company (NYSE:LLY)
Novo Nordisk A/S (NYSE:NVO)
Johnson & Johnson (NYSE:JNJ)
Pfizer, Inc. (NYSE:PFE)
Dr. Reddy's Laboratories Ltd. (NSE:DRREDDY)
Divi's Laboratories Limited (NSE:DIVISLAB)
Business
UNION KOREA PHARM CO.,Ltd is a South Korea-based pharmaceutical company primarily engaged in the research, development, manufacturing, and distribution of ethical pharmaceuticals, over-the-counter medications, and specialized therapeutic injections. The company's core product portfolio comprises systemic antibiotics and anti-infectives, including cephalosporins, penicillins, and aminoglycosides; cardiovascular and circulatory system drugs, including antihypertensives, antithrombotics, and lipid-lowering agents; gastrointestinal and digestive system treatments, including proton pump inhibitors, anti-ulcerants, and digestives; respiratory system remedies, including antitussives, expectorants, and antihistamines; musculoskeletal and central nervous system therapeutics, including non-steroidal anti-inflammatory drugs, analgesics, and muscle relaxants; and specialized nutritional injectables, including multivitamin complexes, antioxidant infusions, and placental extract solutions. In addition to finished dosage formulations under its proprietary labels, the company provides contract manufacturing organization and contract development and manufacturing organization services, producing sterile ampoules, liquid vials, and lyophilized powders for third-party pharmaceutical partners. The company distributes its products to hospitals, clinics, and pharmacies across South Korea and exports finished pharmaceuticals to overseas markets, including regions in Southeast Asia, Central Asia, and the Middle East. Recent strategic and operational developments include the enhancement and automated upgrading of its sterile injectable and lyophilization production lines at its Wonju plant to expand contract manufacturing capacity; portfolio diversification into medical aesthetics, skin booster injectables, and health functional foods; progression of R&D pipelines focused on fixed-dose combination formulations and modified-release therapeutics; and strategic financial restructuring through debt-financing instruments to bolster working capital, support facility modernization, and expand global marketing partnerships. Founded in 1956, UNION KOREA PHARM CO.,Ltd is headquartered in Seongnam-si, Gyeonggi-do, South Korea.